Positron emission tomography imaging of amphetamine‐induced dopamine release in the human cortex: A comparative evaluation of the high affinity dopamine D2/3 radiotracers [11C]FLB 457 and [11C]fallypride

The use of PET and SPECT endogenous competition binding techniques has contributed to the understanding of the role of dopamine in several neuropsychiatric disorders. An important limitation of these imaging studies is the fact that measurements of acute changes in synaptic dopamine have been restricted to the striatum. The ligands previously used, such as [11C]raclopride and [123I]IBZM, do not provide sufficient signal to noise ratio to quantify D2 receptors in extrastriatal areas, such as cortex, where the concentration of D2 receptors is much lower than in the striatum. Given the importance of cortical DA function in cognition, a method to measure cortical dopamine function in humans would be highly desirable. The goal of this study was to compare the ability of two high affinity DA D2 radioligands [11C]FLB 457 and [11C]fallypride to measure amphetamine‐induced changes in DA transmission in the human cortex. D2 receptor availability was measured in the cortical regions of interest with PET in 12 healthy volunteers under control and postamphetamine conditions (0.5 mg kg−1, oral), using both [11C]FLB 457 and [11C]fallypride (four scans per subjects). Kinetic modeling with an arterial input function was used to derive the binding potential (BPND) in eight cortical regions. Under controlled conditions, [11C]FLB 457 BPND was 30–70% higher compared with [11C]fallypride BPND in cortical regions. Amphetamine induced DA release led to a significant decrease in [11C]FLB 457 BPND in five out the eight cortical regions evaluated. In contrast, no significant decrease in [11C]fallypride BPND was detected in cortex following amphetamine. The difference between [11C]FLB 457 and [11C]fallypride ability to detect changes in the cortical D2 receptor availability following amphetamine is related to the higher signal to noise ratio provided by [11C]FLB 457. These findings suggest that [11C]FLB 457 is superior to [11C]fallypride for measurement of changes in cortical synaptic dopamine. Synapse 63:447–461, 2009. © 2009 Wiley‐Liss, Inc.

[1]  C. Winstanley The Orbitofrontal Cortex, Impulsivity, and Addiction , 2007, Annals of the New York Academy of Sciences.

[2]  Pradeep J Nathan,et al.  Small effect of dopamine release and no effect of dopamine depletion on [18F]fallypride binding in healthy humans , 2007, Synapse.

[3]  Ramin V. Parsey,et al.  Optimal Metabolite Curve Fitting for Kinetic Modeling of 11C-WAY-100635 , 2007, Journal of Nuclear Medicine.

[4]  R. P. Maguire,et al.  Consensus Nomenclature for in vivo Imaging of Reversibly Binding Radioligands , 2007, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[5]  H. Moore,et al.  Correlation between PET and microdialysis measurements of amphetamine induced DA release in striatal and extrastriatal brain regions in baboons , 2007 .

[6]  Mark Slifstein,et al.  Amphetamine-induced dopamine release: markedly blunted in cocaine dependence and predictive of the choice to self-administer cocaine. , 2007, The American journal of psychiatry.

[7]  Marie-Claude Asselin,et al.  Quantification of PET Studies with the Very High-Affinity Dopamine D2/D3 Receptor Ligand [11C]FLB 457: Re-Evaluation of the Validity of using a Cerebellar Reference Region , 2007, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[8]  Lars Farde,et al.  Measurement of Methylphenidate-Induced Change in Extrastriatal Dopamine Concentration using [11C]FLB 457 PET , 2007, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[9]  Alain Dagher,et al.  Modeling sensitization to stimulants in humans: an [11C]raclopride/positron emission tomography study in healthy men. , 2006, Archives of general psychiatry.

[10]  Mohammad Sib Ansari,et al.  Amphetamine-Induced Displacement of [18F] Fallypride in Striatum and Extrastriatal Regions in Humans , 2006, Neuropsychopharmacology.

[11]  P. Grasby,et al.  Effect of reduction in endogenous dopamine on extrastriatal binding of [11C]FLB 457 in rat brain—An ex vivo study , 2006, Synapse.

[12]  S. Nishiyama,et al.  Nicotine Normalizes Increased Prefrontal Cortical Dopamine D1 Receptor Binding and Decreased Working Memory Performance Produced by Repeated Pretreatment with MK-801: A PET Study in Conscious Monkeys , 2005, Neuropsychopharmacology.

[13]  Mark Slifstein,et al.  Alcohol Dependence Is Associated with Blunted Dopamine Transmission in the Ventral Striatum , 2005, Biological Psychiatry.

[14]  Matti Laine,et al.  Frontal and Temporal Dopamine Release during Working Memory and Attention Tasks in Healthy Humans: a Positron Emission Tomography Study Using the High-Affinity Dopamine D2 Receptor Ligand [11C]FLB 457 , 2005, The Journal of Neuroscience.

[15]  Mark W. Woolrich,et al.  Advances in functional and structural MR image analysis and implementation as FSL , 2004, NeuroImage.

[16]  Mark Slifstein,et al.  Effect of amphetamine on [18F]fallypride in vivo binding to D2 receptors in striatal and extrastriatal regions of the primate brain: Single bolus and bolus plus constant infusion studies , 2004, Synapse.

[17]  Christer Halldin,et al.  Differentiation of extrastriatal dopamine D2 receptor density and affinity in the human brain using PET , 2004, NeuroImage.

[18]  Kjell Någren,et al.  Alfentanil increases cortical dopamine D2/D3 receptor binding in healthy subjects , 2004, Pain.

[19]  Mark Slifstein,et al.  In vivo affinity of [18F]fallypride for striatal and extrastriatal dopamine D2 receptors in nonhuman primates , 2004, Psychopharmacology.

[20]  Jogeshwar Mukherjee,et al.  Measuring the in Vivo Binding Parameters of [18F]-Fallypride in Monkeys Using a PET Multiple-Injection Protocol , 2004, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[21]  B. Christian,et al.  11C-Fallypride: radiosynthesis and preliminary evaluation of a novel dopamine D2/D3 receptor PET radiotracer in non-human primate brain. , 2004, Bioorganic & medicinal chemistry.

[22]  Sylvain Houle,et al.  Oral D‐amphetamine causes prolonged displacement of [11C]raclopride as measured by PET , 2004, Synapse.

[23]  C. Halldin,et al.  Decreased thalamic D2/D3 receptor binding in drug-naive patients with schizophrenia: a PET study with [11C]FLB 457. , 2003, The international journal of neuropsychopharmacology.

[24]  M. Laakso,et al.  Hippocampal dopamine D2 receptors correlate with memory functions in Alzheimer's disease , 2003, The European journal of neuroscience.

[25]  S. Schulman Continuous infusion , 2003, Haemophilia : the official journal of the World Federation of Hemophilia.

[26]  S. Haber,et al.  Imaging Human Mesolimbic Dopamine Transmission with Positron Emission Tomography. Part II: Amphetamine-Induced Dopamine Release in the Functional Subdivisions of the Striatum , 2003, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[27]  B. Christian,et al.  Brain imaging of 18F‐fallypride in normal volunteers: Blood analysis, distribution, test‐retest studies, and preliminary assessment of sensitivity to aging effects on dopamine D‐2/D‐3 receptors , 2002, Synapse.

[28]  A. Dagher,et al.  Amphetamine-Induced Increases in Extracellular Dopamine, Drug Wanting, and Novelty Seeking: A PET/[11C]Raclopride Study in Healthy Men , 2002, Neuropsychopharmacology.

[29]  Kjell Någren,et al.  Age‐related loss of extrastriatal dopamine D2‐like receptors in women , 2002, Journal of neurochemistry.

[30]  R. V. Van Heertum,et al.  Prefrontal Dopamine D1 Receptors and Working Memory in Schizophrenia , 2002, The Journal of Neuroscience.

[31]  J. Delforge,et al.  Parametric Images of the Extrastriatal D2 Receptor Density Obtained Using a High-Affinity Ligand (FLB 457) and a Double-Saturation Method , 2001, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[32]  K Suzuki,et al.  Reproducibility of [11C]FLB 457 binding in extrastriatal regions , 2001, Nuclear medicine communications.

[33]  Osama Mawlawi,et al.  Imaging Human Mesolimbic Dopamine Transmission with Positron Emission Tomography: I. Accuracy and Precision of D2 Receptor Parameter Measurements in Ventral Striatum , 2001, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[34]  S. Obayashi,et al.  Effect of endogenous dopamine on extrastriatal [11C]FLB 457 binding measured by PET , 2001, Synapse.

[35]  S Tanada,et al.  Age-related reduction of extrastriatal dopamine D2 receptor measured by PET. , 2001, Life sciences.

[36]  Christer Halldin,et al.  Error Analysis for Quantification of [11C]FLB 457 Binding to Extrastriatal D2 Dopamine Receptors in the Human Brain , 2001, NeuroImage.

[37]  V Kaasinen,et al.  Sex differences in extrastriatal dopamine d(2)-like receptors in the human brain. , 2001, The American journal of psychiatry.

[38]  C. Halldin,et al.  Effect of amphetamine on extrastriatal D2 dopamine receptor binding in the primate brain: A PET study , 2000, Synapse.

[39]  Kjell Någren,et al.  Measurement of extrastriatal D2-like receptor binding with [11C]FLB 457 – a test-retest analysis , 2000, European Journal of Nuclear Medicine.

[40]  Lars Farde,et al.  Age-related dopamine D2/D3 receptor loss in extrastriatal regions of the human brain , 2000, Neurobiology of Aging.

[41]  D. Lewis,et al.  Tyrosine Hydroxylase- and Dopamine Transporter-Immunoreactive Axons in the Primate Cerebellum , 2000, Neuropsychopharmacology.

[42]  V Kaasinen,et al.  Extrastriatal dopamine D2 and D3 receptors in early and advanced Parkinson’s disease , 2000, Neurology.

[43]  M. Laruelle Imaging Synaptic Neurotransmission with in Vivo Binding Competition Techniques: A Critical Review , 2000, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[44]  Christer Halldin,et al.  Measurement of Striatal and Extrastriatal Dopamine D1 Receptor Binding Potential With [11C]NNC 112 in Humans: Validation and Reproducibility , 2000, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[45]  Christer Halldin,et al.  PET Mapping of Extrastriatal D2-like Dopamine Receptors in the Human Brain Using an Anatomic Standardization Technique and [11C]FLB 457 , 1999, NeuroImage.

[46]  C. C. Watson,et al.  New, faster, image-based scatter correction for 3D PET , 1999, 1999 IEEE Nuclear Science Symposium. Conference Record. 1999 Nuclear Science Symposium and Medical Imaging Conference (Cat. No.99CH37019).

[47]  C. Halldin,et al.  Quantification of [11C]FLB 457 Binding to Extrastriatal Dopamine Receptors in the Human Brain , 1999, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[48]  D. Wong,et al.  GBR12909 attenuates amphetamine‐induced striatal dopamine release as measured by [11C]raclopride continuous infusion PET scans , 1999, Synapse.

[49]  Christer Halldin,et al.  Extrastriatal dopamine D2 receptor density and affinity in the human brain measured by 3D PET. , 1999, International Journal of Neuropsychopharmacology.

[50]  Bernard Bendriem,et al.  Quantitation of Extrastriatal D2 Receptors Using a Very High-Affinity Ligand (FLB 457) and the Multi-Injection Approach , 1999, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[51]  M Laruelle,et al.  Stability of [123I]IBZM SPECT measurement of amphetamine‐induced striatal dopamine release in humans , 1999, Synapse.

[52]  Roger N. Gunn,et al.  Tracer Kinetic Modeling of the 5-HT1AReceptor Ligand [carbonyl-11C]WAY-100635 for PET , 1998, NeuroImage.

[53]  Christer Halldin,et al.  PET Studies of Binding Competition between Endogenous Dopamine and the D1 Radiotracer [11C]NNC 756 , 1998, NeuroImage.

[54]  Christer Halldin,et al.  A PET-study of [11C]FLB 457 binding to extrastriatal D2-dopamine receptors in healthy subjects and antipsychotic drug-treated patients , 1997, Psychopharmacology.

[55]  W C Eckelman,et al.  Kinetic Modeling of [11C]Raclopride: Combined PET-Microdialysis Studies , 1997, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[56]  L. Seiden,et al.  Evaluation of d‐amphetamine effects on the binding of dopamine D‐2 receptor radioligand, 18F‐fallypride in nonhuman primates using positron emission tomography , 1997, Synapse.

[57]  S. J. Gatley,et al.  Decreased striatal dopaminergic responsiveness in detoxified cocaine-dependent subjects , 1997, Nature.

[58]  W C Eckelman,et al.  Quantification of Amphetamine-Induced Changes in [11C]Raclopride Binding with Continuous Infusion , 1997, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[59]  A. Malhotra,et al.  Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: evidence from a novel positron emission tomography method. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[60]  P B Hoffer,et al.  Microdialysis and SPECT measurements of amphetamine‐induced dopamine release in nonhuman primates , 1997, Synapse.

[61]  J. Krystal,et al.  Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[62]  Christer Halldin,et al.  Autoradiographic localization of extrastriatal D2‐dopamine receptors in the human brain using [125I]epidepride , 1996, Synapse.

[63]  T Suhara,et al.  Carbon-11-FLB 457: a radioligand for extrastriatal D2 dopamine receptors. , 1995, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[64]  M. K. Das,et al.  Fluorinated benzamide neuroleptics--III. Development of (S)-N-[(1-allyl-2-pyrrolidinyl)methyl]-5-(3-[18F]fluoropropyl)-2, 3-dimethoxybenzamide as an improved dopamine D-2 receptor tracer. , 1995, Nuclear medicine and biology.

[65]  D. Charney,et al.  Spect imaging of striatal dopamine release after amphetamine challenge in humans: Relationship between subjective effects and dopamine release , 1995, Schizophrenia Research.

[66]  S. Zoghbi,et al.  Evaluation of ultrafiltration for the free-fraction determination of single photon emission computed tomography (SPECT) radiotracers: beta-CIT, IBF, and iomazenil. , 1994, Journal of pharmaceutical sciences.

[67]  P B Hoffer,et al.  Compartmental modeling of iodine-123-iodobenzofuran binding to dopamine D2 receptors in healthy subjects. , 1994, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[68]  J. Seibyl,et al.  SPECT measurement of benzodiazepine receptors in human brain with iodine-123-iomazenil: kinetic and equilibrium paradigms. , 1994, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[69]  O. Mamer,et al.  Determination of amphetamine, methamphetamine and desmethyldeprenyl in human plasma by gas chromatography/negative ion chemical ionization mass spectrometry. , 1993, Biological mass spectrometry.

[70]  June Corwin,et al.  Early pharmacokinetics and clinical effects of oral d-amphetamine in normal subjects , 1987, Biological Psychiatry.

[71]  M. Mintun,et al.  A quantitative model for the in vivo assessment of drug binding sites with positron emission tomography , 1984, Annals of neurology.

[72]  P. Valdiguie,et al.  Cerebral Circulatory Effects of a Dopaminergic Agonist (Apomorphine) in the Dog , 1982, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[73]  Alan A. Wilson,et al.  First Human Evidence of d-Amphetamine Induced Displacement of a D2/3 Agonist Radioligand: A [11C]-(+)-PHNO Positron Emission Tomography Study , 2008, Neuropsychopharmacology.

[74]  Christer Halldin,et al.  Decreased thalamic D2/D3 receptor binding in drug-naive patients with schizophrenia: a PET study with [11C]FLB 457. , 2003, The international journal of neuropsychopharmacology.

[75]  S. Tanada,et al.  Decreased dopamine D2 receptor binding in the anterior cingulate cortex in schizophrenia. , 2002, Archives of general psychiatry.

[76]  井上 眞 Age-related reduction of extrastriatal dopamine D2 receptor measured by PET , 2002 .

[77]  Stephen M. Smith,et al.  Segmentation of brain MR images through a hidden Markov random field model and the expectation-maximization algorithm , 2001, IEEE Transactions on Medical Imaging.

[78]  M P Sandler,et al.  FDG PET and dual-head gamma camera positron coincidence detection imaging of suspected malignancies and brain disorders. , 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[79]  Julie C. Price,et al.  PET Measurement of Endogenous Neurotransmitter Activity Using High and Low Affinity Radiotracers 1 1Transcripts of the BRAINPET97 discussion of this chapter can be found in Section VIII. , 1998 .

[80]  A. Gjedde,et al.  Quantitative functional brain imaging with positron emission tomography , 1998 .

[81]  M. Laruelle,et al.  Imaging Receptor Occupancy by Endogenous Transmitters in Humans , 1998 .

[82]  Y. Benjamini,et al.  Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .

[83]  A. Hill,et al.  The possible effects of the aggregation of the molecules of haemoglobin on its dissociation curves , 1910 .